Loading…
Loading…
DSS does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for DSS and 80,000+ other tickers.
See exactly how DSS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for DSS and 80,000+ other tickers.
DSS, Inc. is a globally diversified enterprise with operations across numerous industries. In product packaging, the company specializes in manufacturing and distributing custom folding cartons, mailers, photo sleeves, and advanced three-dimensional direct mail products. It also engages in the marketing and distribution of nutritional and personal care items. Within the biotechnology and biohealth sphere, DSS makes strategic investments in and acquires companies dedicated to pioneering drug discovery, prevention, and treatment methodologies for neurological, oncological, and immune-system…
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) today announced that it has withdrawn its previously filed Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission. After careful review of current market conditions and deal terms, management and the Board of Directors concluded that proceeding with the offering at this time would not reflect the value DSS believes it is building for shareholders.
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration has accepte
ROCHESTER, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) announced that its annual report (10-K) for the fiscal year ending December 31, 2025, filed on March 31, 2026, includes an audit opinion from HTL International LLC. that contains a "going concern" qualification. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph and does not represent any change or amendment to the Company's financial statements for the year ended December 31, 2025.
ROCHESTER, N. Y. , April 15, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) today issued the following letter to shareholders from the Interim CEO, Jason Grady, highlighting the Company's operational progress, financial improvements, and strategic initiatives. Dear Fellow Shareholders, Over the past six months, our stock performance has not fully reflected the progress we have made inside DSS.
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology, commercial lending, and securities and investment management, today announced the closing of its previously announced firm commitment underwritten public offering. Gross proceeds to the Company were approximately $1.0 million, before deducting underwriting fees and other offering expenses payable by the Company.